Hutchison China MediTech Ltd.'s investigational cancer therapy fruquintinib in combination with AstraZeneca PLC's Iressa reported positive preliminary results in a phase 2 trial.
The trial assessed the drug combination as a first-line treatment in China as a first-line treatment for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer.
Fruquintinib is an inhibitor of the vascular endothelial growth factor receptor, which enables growth in cancerous cells. The study evaluated the drug in combination with Iressa, a tyrosine kinase inhibitor.
Preliminary results showed that 76% of patients showed a reduction in tumor size, with the drug combination showing a 100% disease control rate, which represents the total proportion of patients who demonstrate a response to treatment.
The drug combination had no serious adverse events or those that lead to death.
Fruquintinib is under joint development in China by Hutchison China MediTech and its partner Eli Lilly and Co..